Skip to content

Author

S. Hohaus

We have 4 of 360 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Rationale and Design of the CARdio-Tox Study: A Prospective Evaluation of Cardiovascular Toxicity in Patients Receiving Chimeric Antigen Receptor-T (CAR-T) Cell Therapy.

Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as an innovative treatment of haematologic malignancies; however, its use is frequently complicated by Cytokine Release Syndrome (CRS), an increasingly recognized driver of cancer therapy-related cardiovascular toxicity (CTR-CVT) able to provoke a wide spectrum...

M. Camilli, M. Ortenzi, L. Leo et al. · 0 citations
Open access Sep 2026

Different treatment eras for relapsed and refractory primary mediastinal B-cell lymphoma patients: accessibility to CAR T cells is associated with a better prognosis in a pooled analysis of the REPRIME-FIL and the CART-SIE studies.

Chimeric Antigen Receptor (CAR) T-cell therapy targeting CD19 has demonstrated efficacy as salvage treatment for patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL), however, a direct comparison between CAR T activity and other salvage treatments has not previously been performed. This s...

A. Guidetti, I. Dogliotti, A. Chiappella et al. · 0 citations
Open access Aug 2026

InflaMix Predicts Severe CRS, ICU Admission, and Progression‐Free Survival After CAR‐T Therapy in LBCL

The prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma receiving commercial CAR‐T cells is evaluated, focusing on treatment‐related toxicities.

Eugenio Galli, D. Mannina, Alessandro Corrente et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.